Menu Search
Equities

MustGrow Biologics Corp

0C0:BER

MustGrow Biologics Corp

Actions
  • Price (EUR)1.25
  • Today's Change0.18 / 16.90%
  • Shares traded597.00
  • 1 Year change+57.59%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MustGrow Biologics Corp. is a Canada-based agricultural biotechnology company. The Company is engaged in developing natural biological products derived from mustard seed to support sustainable farming. Its solutions provide alternatives to banned or restricted synthetic chemicals and fertilizers, promoting organic farming and soil health improvement. The Company develops mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Its TerraSante is Organic Materials Review Institute (OMRI Listed) and Organic Input Material (OIM) registered biofertility product in California, Florida, Arizona, Idaho, Oregon, and Washington. TerraSante provides mustard proteins and carbohydrates to feed the soil microbes. Its TerraMG is an organic plant extract from mustard used to help treat diseases and insect pests, such as nematodes.

  • Revenue in CAD (TTM)4.71m
  • Net income in CAD-423.96k
  • Incorporated2014
  • Employees0.00
  • Location
    MustGrow Biologics Corp1005-201 1st Ave SSaskatoon S7K 1J5CanadaCAN
  • Phone+1 (306) 668-2652
  • Websitehttps://mustgrow.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.